Mirati Therapeutics: Poised For Takeoff

Out of Ignorance profile picture
Out of Ignorance


  • Mirati's PDUFA for adagrasib in treatment of NSCLC is weeks away.
  • In addition to this imminent FDA decision, Mirati has a strong late-stage pipeline with another potential filing in mid-2023.
  • Despite a heavy expense load, Mirati's cash hoard and hefty share price will easily keep it aloft for the near term.
  • Buyout rumors are swirling, offering a potential near-term exit ramp.

Lifting hot air balloon

vuk8691/iStock via Getty Images

This is my first look at Mirati Therapeutics (NASDAQ:MRTX), a stock with multiple catalysts. Mirati boasts a $5.6 billion market cap. It has no FDA approved products, nor any product revenue (10-Q, p. 50

Mirati pipeline


LUMYKRAS initial quarterly sales


Select Company Financials


Data by YCharts

Seeking Alpha 11/28/2022 Mirati news feed


This article was written by

Out of Ignorance profile picture
Writing under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and from ~5 years of focused research on a variety of stocks, in recent years with a primary emphasis on healthcare stocks. I greatly appreciate those who take the time to share their reactions to articles, particularly those who share relevant anecdotes and experiences.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ANY STOCK MENTIONED over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.